You are here: Industry Insights > cipla

News List

Cipla to explore remdesivir multi-drug combination for Covid-19 pharmaceutical-technology
May 20, 2020
India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences’ investigational antiviral drug remdesivir, for the treatment of Covid-19 coronavirus infection.
Cipla enters into a licensing agreement With Gilead to expand access to COVID-19 treatment expresspharma
May 13, 2020
As part of the agreement, Cipla will be permitted to manufacture the API and Finished product, and market it in 127 countries including India and South Africa under Cipla’s own brand name.
IICT develops synthetic process for Favipiravir, transfers to Cipla expresspharma
May 05, 2020
As a collaborative effort with industry, Hyderabad-based CSIR-IICT transferred the entire process and significant quantities of pharma grade API of Favipiravir to Cipla.
CSIR identifies top 25 drugs/drug candidates for repurposing expresspharma
May 04, 2020
Favipiravir, a broad-spectrum inhibitor of viral RNA polymerase, emerges as one of the most promising drugs.
Cipla donates Rs 25 crores for COVID-19 relief fund expresspharma
April 22, 2020
Cipla announced an INR 25 crore fund to support the Indian Government’s efforts to effectively combat the COVID-19 pandemic.
Cipla receives final approval for generic version of Proventil HFA Inhalation Aerosol expresspharma
April 09, 2020
Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol 90mcg (base)/actuation.
Cipla announces completion of phase-3 clinical study for generic version of GSK’s Advair Diskus expresspharma
April 03, 2020
The study, completed in the first attempt, was conducted over a period of 15 months at over 100 sites in the US enrolling 1,400 asthma patients.
Cipla receives final approval for generic version of AstraZeneca Pharmaceutical’s Nexium (Esomeprazole for Oral Suspension 10mg, 20mg and 40mg) expresspharma
March 27, 2020
With this, Cipla has become the first company to file for the 10 mg variant strength of the product.
CSIR-IICT ties up with Cipla to develop anti-COVID-19 drug expresspharma
March 20, 2020
Hyderabad-based CSIR – Indian Institute of Chemical Technology (IICT) has tied up with pharmaceutical giant Cipla to work on development of anti-viral drugs to contain COVID-19.
Cipla seeks favourable policy for domestic pharma cos, ease of doing biz expresspharma
July 30, 2019
Homegrown drug major Cipla has urged the government to increase fund allocation for the healthcare sector, improve ease of doing business and formulate policies that aid the domestic pharmaceutical industry.

Previous page 1 2 3 4 5 6 7 8 Next page